Choose the low-profile DCB with trusted technology and designed for better deliverability.*
IN.PACT™ 018 DCB combines a low-profile design and proven technology to deliver lasting results to your patients with femoropopliteal disease.
Engineered to cross tight lesions and provide better deliverability*
5 Fr compatible
(4–6 mm diameter)
Uses the same proven formulation as IN.PACT™ Admiral™, the DCB physicians choose the most
Features
- Platinum-iridium marker bands
- Coaxial shaft
- FreePac™ coating
- 80 and 130cm catheter lengths
Peel-away balloon protector
The IN.PACT™ 018 DCB features a peel-away balloon protector that helps preserve the integrity of the drug coating.
Expanded platform, trusted data
The Medtronic IN.PACT™ 018 and IN.PACT™ Admiral DCBs allow you to choose your preferred tool, knowing you're using DCBs backed by unmatched safety and efficacy data1 — including five-year data on complex lesions.2
With 75% of patients remaining reintervention-free at five years,1 IN.PACT™ Admiral has the:
- Highest patency benefit through three years1
- Most publications for a DCB‡
The safety and effectiveness of the IN.PACT™ Admiral DCB (.035 in guidewire compatible), as established in the clinical studies that were performed primarily via femoral access, can be considered supportive for the IN.PACT™ 018 DCB. The IN.PACT™ 018 DCB has not been evaluated in a clinical study.
Building on proven technology
The IN.PACT™ 018 DCB uses the same proven formulation as IN.PACT™ Admiral DCB, so interventionalists can expand their treatment options without compromising on safety and effectiveness.
IN.PACT™ DCBs are coated with a combination of paclitaxel and an excipient, urea. The unique formulation allows rapid and efficient delivery of drug to the vessel wall.
Watch this mechanism of action animation to see what makes IN.PACT™ DCBs unique.
Additional resources
Reach a Medtronic sales representative
Contact information
CardioVascular Lifeline Customer Support
24-hour technical support (worldwide)
+1 763-526-7890
rs.cstechsupport@medtronic.com
The safety and effectiveness of the IN.PACT™ Admiral DCB (.035 in guidewire compatible), as established in the clinical studies that were performed primarily via femoral access, can be considered supportive for the IN.PACT™ 018 DCB. The IN.PACT™ 018 DCB has not been evaluated in a clinical study.
*
Data on file with Medtronic.
†
Complications associated with radial access may include but are not limited to: abrupt vessel closure, vessel spasm, perforation or rupture of the artery, dissection, pseudoaneurysm, hematoma, thrombosis, and stroke.
‡
Publications on file with Medtronic.
§
Some restrictions may apply.
References
1
Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. 5-year results from the IN.PACT SFA Trial. Circ Cardiovasc Interv. June 2019;12(6):e007702.
2
Tepe G. 5-year results from the IN.PACT Global Study Prespecified Cohorts: ISR, CTO and Long Lesions. Presented at VIVA 2021.